title: An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children.
abstract: Tetravalent meningococcal serogroups ACWY conjugate vaccines will provide an advantage to those at most risk of invasive meningococcal disease; namely young children. Co-administration of ACWY-TT with DTaP-HBV-IPV/Hib was assessed in a randomized trial in 793 children aged 12-23 months. Pre-specified criteria for non-inferiority of immunogenicity following co-administration versus separate ACWY-TT and DTaP-HBV-IPV/Hib administration were reached. One month post-vaccination, ≥ 97.3% of ACWY-TT vaccinees had rSBA titres ≥ 1:8 (all serogroups). Seroprotection/seropositivity rates against DTaP-HBV-IPV/Hib antigens were ≥ 98.2%. The safety profile of co-administration was similar to that of DTaP-HBV-IPV/Hib alone. ACWY-TT and DTaP-HBV-IPV/Hib co-administration during the second year would facilitate introduction of ACWY-TT into routine toddler vaccination schedules.
authors.affiliation: Pediatrics Infectious Diseases, University Medicine, Mainz, Germany. markus.knuf@hsk-wiesbaden.de
authors.forename: Markus
authors.initials: M
authors.lastname: Knuf
authors.forename: Anna
authors.initials: A
authors.lastname: Pantazi-Chatzikonstantinou
authors.forename: Ulrich
authors.initials: U
authors.lastname: Pfletschinger
authors.forename: Irmingard
authors.initials: I
authors.lastname: Tichmann-Schumann
authors.forename: Hartwig
authors.initials: H
authors.lastname: Maurer
authors.forename: Lothar
authors.initials: L
authors.lastname: Maurer
authors.forename: Thomas
authors.initials: T
authors.lastname: Fischbach
authors.forename: Henrike
authors.initials: H
authors.lastname: Zinke
authors.forename: Heidemarie
authors.initials: H
authors.lastname: Pankow-Culot
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Papaevangelou
authors.forename: Veronique
authors.initials: V
authors.lastname: Bianco
authors.forename: Marie
authors.initials: M
authors.lastname: Van der Wielen
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Miller
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D005260:Female; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D018073:Haemophilus Vaccines; D022401:Meningococcal Vaccines; D011054:Poliovirus Vaccine, Inactivated; D013745:Tetanus Toxoid; D017778:Vaccines, Combined; D018074:Vaccines, Conjugate